Accelerating personalized TCR immunotherapy for microsatellite-stable colorectal cancer with a multimodal prediction model

Active Project Grant Awarded Last action

Award ID
HT9425261E271
Recipient
Awarding agency
Obligated
$999,766

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date 5% complete
Place of performance
Tacoma, WA 98402, USA

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

The Defense Health Agency awarded The Geneva Foundation $999,766 on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to accelerate personalized T-cell receptor immunotherapy for microsatellite-stable colorectal cancer through development of a multimodal prediction model. The project runs through August 31, 2029, with work performed in Tacoma, Washington. This Project Grant is assistance funding supporting biomedical research to transform health care for Service Members through innovative solutions addressing battlefield and clinical medical priorities. The Geneva Foundation is a 501(c)(3) nonprofit research organization that serves as a prime recipient on federal biomedical research and clinical support services for defense and health agencies, with the Defense Health Agency and Department of the Army Medical Command dominating its customer base.

Quick answers

Who received award HT9425261E271?

HT9425261E271 was awarded to The Geneva Foundation by Defense Health Agency (Department of Defense) on September 1, 2026.

How much is award HT9425261E271 worth?

$999,766 has been obligated on HT9425261E271.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login